Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jun 5;9(43):27233-27241.
doi: 10.18632/oncotarget.25519.

Construction and characterization of a new TRAIL soluble form, active at picomolar concentrations

Affiliations

Construction and characterization of a new TRAIL soluble form, active at picomolar concentrations

Matias Eliseo Melendez et al. Oncotarget. .

Abstract

Apoptosis induction has emerged as a treatment option for anticancer therapy. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), a type II transmembrane protein, is a potent and specific pro-apoptotic protein ligand, which activates the extrinsic apoptosis pathway of the cell death receptors. Here we describe the construction and characterization of a new soluble TRAIL, sfTRAIL, stabilized with the trimerization Foldon domain from the Fibritin protein of the bacteriophage T4. Supernatants of 0.22 μM-filtered supernatants were produced in Vero-transduced cells with HSV1-derived viral amplicon vectors. Experiments were undertaken in two known TRAIL-sensitive (U373 and MDA.MB.231) and two TRAIL-resistant (MCF7 and A549) cell lines, to determine (i) whether the sfTRAIL protein is synthetized and, (ii) whether sfTRAIL could induce receptor-mediated apoptosis. Our results showed that sfTRAIL was able to induce apoptosis at concentrations as low as 1899.29 pg/mL (27.71 pM), independently of caspase-9 activation, and reduction in cell viability at 998.73 fM.

Keywords: TRAIL; amplicon vectors; apoptosis; cancer treatment.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST Authors MEM and ALC have a patent for this technology.

Figures

Figure 1
Figure 1
(A) Schematic representation of the sfTRAIL protein; (B) Western blot analysis of sfTRAIL protein expression. Vero cells were transduced with pA.EUA1 or pA.sfTRAIL amplicon vectors, at MOI1. Anti-TRAIL antibody and anti-β-actin were used.
Figure 2
Figure 2. Cell viability (MTS) of cells incubated with sfTRAIL supernatants
Values shown are the mean value (± SDs) of triplicates. (SN) means supernatants. sfTRAIL concentration in supernatants was 1899.29 pg/mL. Data represents three experiments performed in triplicate. p-value were assessed by Student’s t-test.
Figure 3
Figure 3. Western blot analysis of sfTRAIL-mediated apoptosis induction. sfTRAIL-mediated apoptosis induction of A549, MCF7, U373 and MDA-MB-231 cells, cultured in conditioned media, at 2h, 4h and 8h post-induction (PI)
UTC, untreated control.
Figure 4
Figure 4. Cell viability (MTS) of cells incubated with sfTRAIL supernatants. Values shown are the mean value (± SDs) of three experiments performed in triplicate (Stock A, B and C)
(SN) means supernatants; NTC (SN) represents supernatants of non-transduced cells; * indicates p-value (Student’s t-test), where ** means p-value=0.0032 and *** p-value<0.0001.

Similar articles

Cited by

References

    1. Savill J, Fadok V. Corpse clearance defines the meaning of cell death. Nature. 2000;407:784–8. https://doi.org/10.1038/35037722. - DOI - PubMed
    1. Ashkenazi A, Holland P, Eckhardt SG. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL) J Clin Oncol. 2008;26:3621–30. https://doi.org/10.1200/JCO.2007.15.7198. - DOI - PubMed
    1. Wiezorek J, Holland P, Graves J. Death receptor agonists as a targeted therapy for cancer. Clin Cancer Res. 2010;16:1701–8. https://doi.org/10.1158/1078-0432.CCR-09-1692. - DOI - PubMed
    1. Holland PM. Death receptor agonist therapies for cancer, which is the right TRAIL? Cytokine Growth Factor Rev. 2014;25:185–93. https://doi.org/10.1016/j.cytogfr.2013.12.009. - DOI - PubMed
    1. Hymowitz SG, O’Connell MP, Ultsch MH, Hurst A, Totpal K, Ashkenazi A, de Vos AM, Kelley RF. A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL. Biochemistry. 2000;39:633–40. https://doi.org/10.1021/bi992242l. - DOI - PubMed

LinkOut - more resources